GeneKeys, LLC is a contract research organization founded by Dr. Jian-xing Ma, an experienced retinal biologist. After many years studying retinal pathologies, Dr. Ma optimized a hyperoxia induced neovascularization model in rats. Not only was this model ideal for studying retinal neovascularization, but also vascular hyperpermeability. Dr. Ma assembled a group of molecular biologists to form GeneKeys LLC. GeneKeys is currently testing anti-angiogenic compounds in hopes of abating the complications of diabetic retinopathy. One compound in particular has shown promise for potential commercialization
